<DOC>
	<DOCNO>NCT01177956</DOCNO>
	<brief_summary>The primary objective trial assess antitumor activity safety profile cetuximab give combination cisplatin + 5-Fluorouracil ( 5-FU ) first-line treatment recurrent and/or metastatic Squamous Cell Carcinoma Head Neck ( SCCHN ) Asian subject .</brief_summary>
	<brief_title>A Trial Determine Safety Anti-tumor Activity Profile Combination Cetuximab Concomitant Cisplatin Plus 5-Fluorouracil ( 5-FU ) Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Signed write informed consent Inpatient Greater equal ( &gt; = ) 18 year age Histologically cytologically confirm diagnosis SCCHN Recurrent and/or metastatic SCCHN suitable local therapy Presence least 1 measurable lesion identify either compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) accord modify WHO criteria Karnofsky performance status ( KPS ) &gt; = 80 percent trial entry Neutrophils &gt; = 1.5*10^9 per liter ( L ) , platelet count &gt; = 100*10^9 per L , hemoglobin &gt; = 90 gram per liter ( g/L ) Total bilirubin less equal ( &lt; = ) 2*upper limit normal ( ULN ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; =3*ULN Serum creatinine &lt; =133 micromole per liter ( mcmol/L ) Serum calcium within normal range Effective contraception procreative potential exists ( applicable male female subject ) Prior systemic chemotherapy , except give part multimodal treatment complete 6 month prior trial entry Surgery ( exclude prior diagnostic biopsy ) irradiation within 4 week trial entry Nasopharyngeal carcinoma Active infection ( infection require IV antibiotic ) , include active tuberculosis , know declared human immunodeficiency virus ( HIV ) Uncontrolled diabetes mellitus , pulmonary fibrosis , acute pulmonary disorder , interstitial pneumonia , cardiac failure liver failure Uncontrolled hypertension define systolic blood pressure &gt; =180 millimeter mercury ( mmHg ) and/or diastolic blood pressure &gt; =130 mmHg rest condition Pregnancy ( absence confirm serum beta human chorionic gonadotrophin [ betaHCG ] test ) breastfeeding Concomitant chronic systemic immune therapy hormonal therapy cancer therapy Other concomitant anticancer therapy Documented symptomatic brain leptomeningeal metastasis Clinically relevant coronary artery disease history myocardial infarction last 12 month high risk uncontrolled arrhythmia uncontrolled cardiac insufficiency Medical psychological condition would permit subject complete trial sign informed consent Known drug abuse ( exception alcohol abuse ) Known hypersensitivity allergic reaction component trial treatment Previous treatment monoclonal antibody therapy , signal transduction inhibitor epidermal growth factor receptor ( EGFR ) target therapy Previous current squamous cell carcinoma ( SCC ) Evidence previous malignancy within last 5 year Signs symptom suggestive transmissible spongiform encephalopathy , family member suffer ( ed ) Intake investigational medication within 30 day trial entry Legal incapacity limit legal capacity Other significant disease Investigator 's opinion would exclude subject trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Recurrent and/or metastatic squamous cell carcinoma head neck</keyword>
	<keyword>1st-line</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>EMR 62241 -055</keyword>
	<keyword>Merck KGaA</keyword>
	<keyword>Recurrent and/or metastatic squamous cell carcinoma head neck ( SCCHN )</keyword>
</DOC>